NCT06626737: Dapagliflozin in Allo-HCT for aGVHD
- State
- Under way
- Phase
- Phase 2
- People
- 72 planned
- Started
- 26 Apr 2025
- Primary completion
- 31 Dec 2025
- Arms
- Dapagliflozin arm
- Results
- None posted
- 4 Oct 2024: Trial registered
- 26 Apr 2025: Trial started
A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set
Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.
Kind of treatment: Drug.
Also known as Dapagliflozin component qternmet, Dapagliflozin (DAPA), Dapagliflozin 10 MG, Dapagliflozin 10 mg daily, Qternmet xr component dapagliflozin.
Registries searched: ClinicalTrials.gov, through 17 Nov 2026.